P. Siliphaivanh

发表

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Shuxia Zhao, Leigh Zawel, Stephen Fawell, 2013, Cancer discovery.

Enantioselective total synthesis of (+)-leucascandrolide A macrolactone.

M. Crimmins, P. Siliphaivanh, 2003, Organic letters.

Enantioselective Total Synthesis of (+)‐Leucascandrolide: A Macrolactone.

M. Crimmins, P. Siliphaivanh, 2004 .

Design of novel histone deacetylase inhibitors.

A. Kral, Karin M. Otte, Thomas A. Miller, 2007, Bioorganic & medicinal chemistry letters.

Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.

C. Kenific, Melissa Chenard, A. Kral, 2014, ACS medicinal chemistry letters.

Label-Free, LC-MS-Based Assays to Quantitate Small-Molecule Antagonist Binding to the Mammalian BLT1 Receptor

R. Myers, D. McLaren, Richard J Visconti, 2017, SLAS discovery : advancing life sciences R & D.

Immunopharmacology and in fl ammation Anti-in fl ammatory actions of Chemoattractant Receptor-homologous molecule expressed on Th 2 by the antagonist MK-7246 in a novel rat model of Alternaria alternata elicited pulmonary in fl ammation

Raquel S. Sevilla, J. Klappenbach, Hyun-Hee Lee, 2014 .

Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5).

M. Altman, Haiyan Xu, P. Siliphaivanh, 2020, ACS medicinal chemistry letters.

Purine derivatives as potent gamma-secretase modulators.

C. Kenific, A. Szewczak, J. Crispino, 2010, Bioorganic & medicinal chemistry letters.

Derives du benzothiophene

Karin M. Otte, Thomas A. Miller, J. Methot, 2006 .

Total Synthesis of Gypsetin, Deoxybrevianamide E, Brevianamide E, and Tryprostatin B: Novel Constructions of 2,3-Disubstituted Indoles

S. Danishefsky, P. Siliphaivanh, J. Schkeryantz, 1999 .

Structural insights on ligand recognition at the human leukotriene B4 receptor 1

V. Katritch, G. Han, V. Cherezov, 2021, Nature Communications.

Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-Oncology

J. O'neil, J. Cumming, A. Palani, 2021, ACS medicinal chemistry letters.

Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers.

G. Naumov, U. Philippar, A. Petrocchi, 2016, Journal of medicinal chemistry.

The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer.

Ryan V. Quiroz, Daniel S Spellman, Haiyan Xu, 2021, Journal of medicinal chemistry.

Identification of Potent Reverse Indazole Inhibitors for HPK1.

X. Fradera, Haiyan Xu, M. Bittinger, 2021, ACS medicinal chemistry letters.

Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1).

J. Grimm, A. Kral, A. Szewczak, 2008, Bioorganic & medicinal chemistry letters.

Quality by design (QbD) of amide isosteres: 5,5-Disubstituted isoxazolines as potent CRTh2 antagonists with favorable pharmacokinetic and drug-like properties.

Xiaohong Zhu, A. Palani, Jie Wu, 2014, Bioorganic & medicinal chemistry letters.